Gilles Devouassoux
Departement of Pulmonology, Croix-Rousse Hospital, Hospices Civils de Lyon · Hospices Civils de Lyon
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Gilles Devouassoux as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 06:28 UTC. Open this list on ClinicalTrials.gov
- Ph4NCT05626777 · Symptoms Control and adhErenCe Assessment During Treatment With MepolizUmab New pREfilled DevicesHospices Civils de Lyon · active not recruiting · Asthma · principal investigator
- Ph2NCT05563168 · Study Evaluating Diltiazem in Combination With Standard Treatment in the Management of Patients Hospitalized With COVID-19 PneumoniaHospices Civils de Lyon · withdrawn · COVID-19 · principal investigator
- N/ANCT02593279 · AVAD: Asthma With Small Airways DysfunctionHospices Civils de Lyon · terminated · ASTHMA · principal investigator
- N/ANCT01885247 · 4-10 Week Observational Study Comparing 3 Management Strategies for Obstructive Chronic BronchoPneumopathy (OCBP) in Common Clinical PracticeHospices Civils de Lyon · unknown · Obstructive Chronic BronchoPneumopathy (OCBP) · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 06:28 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 06:28 UTC. The ranking covers the 200 most relevant of 7 PubMed records, and a shared surname and initials can bring in a namesake. All 7 on PubMed
- Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study.Lancet Respir Med · 2013183 citationsRCR 7.2
- 146 citationsRCR 4.7
- The clinical benefit of mepolizumab replacing omalizumab in uncontrolled severe eosinophilic asthma.Allergy · 2019134 citationsRCR 6.8
- Sleep apnea is associated with bronchial inflammation and continuous positive airway pressure-induced airway hyperresponsiveness.J Allergy Clin Immunol · 200790 citationsRCR 2.8
- COMET: a multicomponent home-based disease-management programme versus routine care in severe COPD.Eur Respir J · 201864 citationsRCR 3.8
- Benefit of switching to mepolizumab from omalizumab in severe eosinophilic asthma based on patient characteristics.Respir Res · 202132 citationsRCR 2.2
- Switching to twice-yearly depemokimab from mepolizumab/benralizumab in severe asthma: a multicenter, randomized, double-blind, phase 3A clinical trial (NIMBLE).Am J Respir Crit Care Med · 202612 citationsRCR 6.0